RLIP76 Regulates PI3K/Akt Signaling and Chemo-Radiotherapy Resistance in Pancreatic Cancer

Targeting Phosphoinositide 3-Kinase Pathways in Pancreatic Cancer – from Molecular Signalling to Clinical Trials

(2012) Marco Falasca et al.   Anti-Cancer Agents in Medicinal Chemistry

Anti-cancer effects of novel flavonoid vicenin-2 as a single agent and in synergistic combination with docetaxel in prostate cancer

(2011) Lokesh Dalasanur Nagaprashantha et al.   BIOCHEMICAL PHARMACOLOGY

Targeting p53-Null Neuroblastomas through RLIP76

(2011) J. Singhal et al.   Cancer Prevention Research

2'-Hydroxyflavanone inhibits proliferation, tumor vascularization and promotes normal differentiation in VHL-mutant renal cell carcinoma

(2011) L. D. Nagaprashantha et al.   CARCINOGENESIS

Glutathione-Conjugate Transport by RLIP76 Is Required for Clathrin-Dependent Endocytosis and Chemical Carcinogenesis

(2011) S. S. Singhal et al.   MOLECULAR CANCER THERAPEUTICS

Challenges of drug resistance in the management of pancreatic cancer

(2010) Rizwan Sheikh et al.   Expert Review of Anticancer Therapy

Oncogenic Kras Requires Simultaneous PI3K Signaling to Induce ERK Activation and Transform Thyroid Epithelial Cells In vivo

(2009) K. A. Miller et al.   CANCER RESEARCH

RLIP76: A Target for Kidney Cancer Therapy

(2009) S. S. Singhal et al.   CANCER RESEARCH

Regression of prostate cancer xenografts by RLIP76 depletion

(2008) Sharad S. Singhal et al.   BIOCHEMICAL PHARMACOLOGY

Absence of E-Cadherin Expression Distinguishes Noncohesive from Cohesive Pancreatic Cancer

(2008) J. M. Winter et al.   CLINICAL CANCER RESEARCH

RLIP76 and Cancer

(2008) S. Awasthi et al.   CLINICAL CANCER RESEARCH

Contrast-Enhanced 18F-FDG PET/CT: 1-Stop-Shop Imaging for Assessing the Resectability of Pancreatic Cancer

(2008) K. Strobel et al.   JOURNAL OF NUCLEAR MEDICINE